Bing Sun1, Linda Abadjian2, Alexander Monto3,4, Heather Freasier3, Lynn Pulliam1,3,4. 1. Department of Laboratory Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA. 2. Department of Mental Health, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA. 3. Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA. 4. University of California, San Francisco, San Francisco, California, USA.
Abstract
BACKGROUND: Chronic inflammation in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection increases cognitive impairment. With newer, direct-acting antiviral therapies for HCV, our objective was to determine whether chronic inflammation would be decreased and cognition improved with HCV sustained viral response (SVR) in coinfection. METHODS: We studied 4 groups longitudinally: 7 HCV-monoinfected and 12 HIV/HCV-coinfected persons before and after treatment for HCV, 12 HIV-monoinfected persons, and 9 healthy controls. We measured monocyte activation and gene expression, monocyte-derived exosome micro-ribonucleic acid (miRNA) expression, plasma inflammation, and cognitive impairment before and after therapy. RESULTS: Plasma soluble CD163 and neopterin were decreased in HCV mono- and coinfected persons. Blood CD16+ monocytes were decreased in coinfection after HCV treatment. Global deficit score improved 25% in coinfection with the visual learning/memory domain the most improved. Hepatitis C virus SVR decreased monocyte interferon genes MX1, IFI27, and CD169 in coinfection and MX1, LGALS3BP, and TNFAIP6 in HCV monoinfection. Monocyte exosomes from coinfected persons increased in microRNA (miR)-19a, miR-221, and miR-223, all of which were associated with decreasing inflammation and nuclear factor-κB activation. CONCLUSIONS: Hepatitis C virus cure in coinfection brings monocyte activation to levels of HIV alone. Cognitive impairment is significantly improved with cure but not better than HIV infection alone, which strong suggests that cognitive impairment was driven by both HIV and HCV.SummaryHCV cure in HIV coinfection improves monocyte and plasma activation markers and increases cognitive function in the visual learning/memory domain.
BACKGROUND: Chronic inflammation in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection increases cognitive impairment. With newer, direct-acting antiviral therapies for HCV, our objective was to determine whether chronic inflammation would be decreased and cognition improved with HCV sustained viral response (SVR) in coinfection. METHODS: We studied 4 groups longitudinally: 7 HCV-monoinfected and 12 HIV/HCV-coinfected persons before and after treatment for HCV, 12 HIV-monoinfected persons, and 9 healthy controls. We measured monocyte activation and gene expression, monocyte-derived exosome micro-ribonucleic acid (miRNA) expression, plasma inflammation, and cognitive impairment before and after therapy. RESULTS: Plasma soluble CD163 and neopterin were decreased in HCV mono- and coinfected persons. Blood CD16+ monocytes were decreased in coinfection after HCV treatment. Global deficit score improved 25% in coinfection with the visual learning/memory domain the most improved. Hepatitis C virus SVR decreased monocyte interferon genes MX1, IFI27, and CD169 in coinfection and MX1, LGALS3BP, and TNFAIP6 in HCV monoinfection. Monocyte exosomes from coinfected persons increased in microRNA (miR)-19a, miR-221, and miR-223, all of which were associated with decreasing inflammation and nuclear factor-κB activation. CONCLUSIONS: Hepatitis C virus cure in coinfection brings monocyte activation to levels of HIV alone. Cognitive impairment is significantly improved with cure but not better than HIV infection alone, which strong suggests that cognitive impairment was driven by both HIV and HCV.SummaryHCV cure in HIV coinfection improves monocyte and plasma activation markers and increases cognitive function in the visual learning/memory domain.
Authors: Felix Kleefeld; Sophie Heller; Patrick Ingiliz; Heiko Jessen; Anders Petersen; Ute Kopp; Antje Kraft; Katrin Hahn Journal: J Neurovirol Date: 2018-05-21 Impact factor: 2.643
Authors: Philip J Ellery; Emma Tippett; Ya-Lin Chiu; Geza Paukovics; Paul U Cameron; Ajantha Solomon; Sharon R Lewin; Paul R Gorry; Anthony Jaworowski; Warner C Greene; Secondo Sonza; Suzanne M Crowe Journal: J Immunol Date: 2007-05-15 Impact factor: 5.422
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon P Moon; Clinton B Wright; Ralph L Sacco; Mitchell S V Elkind Journal: PLoS One Date: 2019-04-01 Impact factor: 3.240
Authors: Rebeca S De Pablo-Bernal; M Reyes Jimenez-Leon; Laura Tarancon-Diez; Alicia Gutierrez-Valencia; Ana Serna-Gallego; Maria Trujillo-Rodriguez; Ana I Alvarez-Rios; Yusnelkis Milanes-Guisado; Nuria Espinosa; Cristina Roca-Oporto; Pompeyo Viciana; Luis F Lopez-Cortes; Ezequiel Ruiz-Mateos Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191